A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...